Статья
Повышение натрийуретических пептидов, не ассоциированное с сердечной недостаточностью
Натрийуретические пептиды (НУП) являются ключевыми диагностическими и прогностическими биомаркерами для пациентов с сердечной недостаточностью (СН). Основным механизмом повышения уровней НУП в сыворотке крови, что характерно для СН, является секреция в ответ на растяжение стенки миокарда. Вместе с тем, по данным отечественной и зарубежной литературы сообщается о повышении НУП при целом ряде других состояний, не ассоциированных с СН. Изучение данных причин и механизмов необходимо для совершенствования дифференциальной диагностики СН.В данной статье рассматриваются механизмы повышения НУП и их диагностическая ценность при СН, а также целом ряде других состояний, таких как острый коронарный синдром и ишемическая болезнь сердца, фибрилляция предсердий, физические нагрузки, почечная недостаточность, прием лекарственных препаратов, обладающих кардиотоксичностью (химиопрепараты), и сакубитрила/валсартана. Также приводятся сведения о возможности определения НУП в биологических жидкостях, полученных неинвазивным путем: моче и ротовой жидкости.
1. Чаулин А. М., Карслян Л. С., Григорьева Е. В. и др. Клинико-диагностическая ценность кардиомаркеров в биологических жидкостях человека. Кардиология. 2019;59(11):66-75. doi:10.18087/cardio.2019.11.n414.
2. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol. 2011;57(2):131-40. doi:10.1016/j.jjcc.2011.01.002.
3. Vinnakota S, Chen HH. The Importance of Natriuretic Peptides in Cardiometabolic Diseases. J Endocr Soc. 2020;4(6):bvaa052. doi:10.1210/jendso/bvaa052.
4. Nakao K, Sugawara A, Morii N, et al. The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol. 1986;31(1):101-3. doi:10.1007/BF00870995.
5. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6(3):257-60. doi:10.1016/j.ejheart.2003.12.015.
6. Abassi Z, Karram T, Ellaham S, et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102(3):223-41. doi:10.1016/j.pharmthera.2004.04.004.
7. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-68. doi:10.1016/j.jacc.2007.09.021.
8. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161. doi:10.1161/CIR.0000000000000509.
10. Joharimoghadam A, Tajdini M, Bozorgi A. Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up. Kardiol Pol. 2017;75(1):71-7. doi:10.5603/KP.a2016.0097.
11. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004;147(6):1078-84. doi:10.1016/j.ahj.2004.01.013.
12. Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151(5):999-1005. doi:10.1016/j.ahj.2005.10.011.
13. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004;164(20):2247-52. doi:10.1001/archinte.164.20.2247.
14. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90(3):254-8. doi:10.1016/s0002-9149(02)02464-5.
15. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976-82. doi:10.1016/s0735-1097(02)02059-4.
16. Lam CS, Cheng S, Choong K, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58(6):618-26. doi:10.1016/j.jacc.2011.03.042.
17. Clerico A, Fontana M, Vittorini S, Emdin M. The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: proposal for a working hypothesis. Clin Chim Acta. 2009;405(1-2):1-7. doi:10.1016/j.cca.2009.03.050.
18. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49(1):109-16. doi:10.1016/j.jacc.2006.10.040.
19. Kawano H, Nagayoshi Y, Soejima H, et al. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram. Menopause. 2008;15(2):352-6. doi:10.1097/gme.0b013e31806548f6.
20. Saenger AK, Dalenberg DA, Bryant SC, et al. Pediatric brain natriuretic peptide concentrations vary with age and sex and appear to be modulated by testosterone. Clin Chem. 2009;55(10):1869-75. doi:10.1373/clinchem.2009.123778.
21. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44(2):335-9. doi:10.1016/j.jacc.2004.04.033.
22. Bjorklund E, Jernberg T, Johanson P, et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart. 2006;92(6):735-40. doi:10.1136/hrt.2005.072975.
23. Siva Sankara C, Rajasekhar D, Vanajakshamma V, et al. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention. Indian Heart J. 2015;67(4):318-27. doi:10.1016/j.ihj.2015.04.023.
24. Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Combined measurement of soluble ST2 and Aminoterminal pro-B-Type natriuretic peptide provides early risk assessment of severity in cardiogenic shock complicating acute coronary syndrome. Crit Care Med. 2017;45:e666-e73. doi:10.1097/CCM.0000000000002336.
25. Wang YP, Wang JH, Wang XL, et al. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. J Cell Mol Med. 2017;21(11):2677-84. doi:10.1111/jcmm.13183.
26. Vogiatzis I, Dapcevic I, Datsios A, et al. A Comparison of Prognostic Value of the Levels of ProBNP and Troponin T in Patients with Acute Coronary Syndrome (ACS). Med Arch. 2016;70(4):269-73. doi:10.5455/medarh.2016.70.269-273.
27. Schellings DA, Adiyaman A, Dambrink JE, et al. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores. Vasc Health Risk Manag. 2016;12:471-6. doi:10.2147/VHRM.S117204.
28. Savonitto S, Morici N, Nozza A, et al. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diab Vasc Dis Res. 2018;15(1):14-23. doi:10.1177/1479164117735493.
29. Mishra RK, Beatty AL, Jaganath R, et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. J Am Heart Assoc. 2014;3(4):e000907. doi:10.1161/JAHA.114.000907.
30. Morello A, Lloyd-Jones DM, Chae CU, et al. Association of atrial fibrillation and aminoterminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J. 2007;153(1):90-7. doi:10.1016/j.ahj.2006.10.005.
31. Richards M, Di Somma S, Mueller C, et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail. 2013;1(3):192-9. doi:10.1016/j.jchf.2013.02.004.
32. Mandalenakis Z, Eriksson H, Welin L, et al. Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923. Int J Cardiol. 2014;171(1):44-8. doi:10.1016/j.ijcard.2013.11.042.
33. Simmers D, Potgieter D, Ryan L, et al. The use of preoperative B-type natriuretic peptide as a predictor of atrial fibrillation after thoracic surgery: systematic review and metaanalysis. J Cardiothorac Vasc Anesth. 2015;29(2):389-95. doi:10.1053/j.jvca.2014.05.015.
34. Ng LL, Loke IW, Davies JE, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol. 2005;45(7):1043-50. doi:10.1016/j.jacc.2004.12.058.
35. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int. 2001;59(5):1928-34. doi:10.1046/j.1523-1755.2001.0590051928.x.
36. Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582-6. doi:10.1016/j.jacc.2005.10.038.
37. Forfia PR, Watkins SP, Rame JE, et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45(10):1667-71. doi:10.1016/j.jacc.2005.01.046.
38. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinatio -nal Study. Am J Kidney Dis. 2003;41(3):571-79. doi:10.1053/ajkd.2003.50118.
39. Scharhag J, Herrmann M, Urhausen A, et al. Independent elevations of N-terminal probrain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. Am Heart J. 2005;150(6):1128-34. doi:10.1016/j.ahj.2005.01.051.
40. Scherr J, Braun S, Schuster T, et al. 72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon. Med Sci Sports Exerc. 2011;43(10):1819-27. doi:10.1249/MSS.0b013e31821b12eb.
41. Perrone MA, Macrini M, Maregnani A, et al. The effects of a 50 km ultramarathon race on high sensitivity cardiac troponin I and NT-proBNP in highly trained athletes. Minerva Cardioangiol. 2020;68(4):305-312. doi:10.23736/S0026-4725.20.05281-0.
42. Martmez-Navarro I, Sanchez-Gomez JM, Collado-Boira EJ, et al. Cardiac Damage Biomarkers and Heart Rate Variability Following a 118-Km Mountain Race: Relationship with Performance and Recovery. J Sports Sci Med. 2019;18(4):615-22.
43. Schwartz P, Piper HM, Spahr R, Spieckermann PG. Ultrastructure of cultured adult myocardial cells during anoxia and reoxygenation. Am J Pathol. 1984;115(3):349-61.
44. Hinrichs L, Mrotzek SM, Mincu RI, et al. Troponins and Natriuretic Peptides in CardioOncology Patients-Data From the ECoR Registry. Front Pharmacol. 2020;11:740. doi:10.3389/fphar.2020.00740.
45. King JB, Bress AP, Reese AD, Munger MA. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy. 2015;35(9):823-37. doi:10.1002/phar.1629.
46. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342-7. doi:10.1136/heartjnl-2014-306775.
47. Solter PF, Oyama MA, Sisson DD. Canine heterophilic antibodies as a source of false-positive B-type natriuretic peptide sandwich ELISA results. Vet Clin Pathol. 2008;37(1):86-95. doi:10.1111/j.1939-165X.2008.00002.x.
48. Collin-Chavagnac D, Manchon M, Traulle C, Bernon H. False-positive BNP results in a 78-year-old man caused by monoclonal IgM-kappa: a case report. Clin Chim Acta. 2007;384(1-2):179. doi:10.1016/j.cca.2007.05.020.
49. Xu L, Li H, Yang S, et al. Interference in the indirect antiglobulin test and direct antiglobulin test from rheumatoid factor. J Int Med Res. 2020;48(3):300060519892386. doi:10.1177/0300060519892386.
50. Saenger AK, Jaffe AS, Body R, et al. Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). Clin Chem Lab Med. 2019;57(5):633-40. doi:10.1515/cclm-2018-0905.
51. Daves M, Salvagno GL, Cemin R, et al. Influence of hemolysis on routine laboratory cardiac marker testing. Clin Lab. 2012;58(3-4):333-6.